Patient Square Capital LP Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX

Patient Square Capital LP bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 316,312 shares of the company’s stock, valued at approximately $4,299,000. Amylyx Pharmaceuticals comprises about 1.1% of Patient Square Capital LP’s holdings, making the stock its 18th largest position. Patient Square Capital LP owned about 0.29% of Amylyx Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Adage Capital Partners GP L.L.C. lifted its stake in Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after acquiring an additional 3,102,395 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Amylyx Pharmaceuticals by 109.9% during the second quarter. Geode Capital Management LLC now owns 1,692,413 shares of the company’s stock valued at $10,851,000 after purchasing an additional 886,252 shares in the last quarter. Saturn V Capital Management LP lifted its position in shares of Amylyx Pharmaceuticals by 34.4% during the second quarter. Saturn V Capital Management LP now owns 3,260,570 shares of the company’s stock valued at $20,900,000 after purchasing an additional 834,134 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Amylyx Pharmaceuticals by 17.2% during the third quarter. Vanguard Group Inc. now owns 5,273,750 shares of the company’s stock worth $71,670,000 after purchasing an additional 775,722 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Shares of Amylyx Pharmaceuticals stock opened at $14.01 on Monday. The stock has a market capitalization of $1.54 billion, a P/E ratio of -7.78 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a 52-week low of $2.60 and a 52-week high of $17.49. The stock’s 50-day simple moving average is $13.47 and its 200 day simple moving average is $12.83.

Insider Buying and Selling

In related news, CFO James M. Frates sold 3,326 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $11.11, for a total transaction of $36,951.86. Following the sale, the chief financial officer directly owned 177,104 shares in the company, valued at approximately $1,967,625.44. This represents a 1.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Joshua B. Cohen sold 1,974 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.83, for a total transaction of $27,300.42. Following the completion of the transaction, the chief executive officer directly owned 3,379,465 shares of the company’s stock, valued at approximately $46,738,000.95. This trade represents a 0.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 157,783 shares of company stock valued at $2,122,808. Corporate insiders own 12.30% of the company’s stock.

Wall Street Analyst Weigh In

AMLX has been the subject of several analyst reports. HC Wainwright increased their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Bank of America increased their price target on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Finally, Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $18.63.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.